Executive committee

Our executive team is comprised of senior leaders from across the Company. Together, they form a forward-thinking, collaborative, multicultural group of leaders

Chief Executive Officer

Michele Antonelli

Michele Antonelli is a seasoned biopharmaceutical executive with extensive expertise in both manufacturing and commercial activities.

Michele Antonelli previously worked at UCB where he held roles of various responsibility and scope, most recently serving as Executive Vice President and Head of lmmunology Europe, overseeing the region’s commercial, medical, and market access activities.

Prior to joining UCB, Michele Antonelli spent 16 years at Merck Serono, ultimately serving as Senior Vice President and Global Head of Biotech Manufacturing and Process Development.

He is Swiss and Italian, and graduated as Doctor in Sciences from University of Bari. He trained in Biotechnology at Catholic University in Piacenza and at Iowa State University in Ames, Iowa.

Chief Financial Officer

Nicola Lamacchia

Nicola joined Stallergenes Greer in March 2017 as Head of Finance for Europe and International with a long-standing experience as business partner in biotechmanufacturing and commercial management.

Prior to joining Stallergenes Greer, he was Head of Finance for International at Shire, leading the creation of a new financial framework and supporting the company’s growth and expansion.

Prior to Shire, he held several country, regional and division-level financial roles at Merck Serono, including Head of Divisional Controlling for the Neurology, Fertility and Endocrinology business, Head of Commercial Europe Finance, Global Biotech Manufacturing Controller, Finance and Logistic Director.

He is Swiss and Italian and holds a Master’s Degree in Business and Economics from the Bocconi University in Milan, and a Business and Leadership Program MBA from MIT-Sloan.

General Counsel

Valérie Benhamou

Valérie Benhamou was appointed General Counsel in 2019. She has more than 20 years of experience in pharmaceutical and medical device law. Valérie joined Stallergenes Greer in 2017 from Abbott, where she was Senior Legal Counsel for France, Benelux and Africa. 

Prior to Abbott, Valérie Benhamou served as Senior counsel for Bristol-Myers Squibb where she provided legal support to all divisions in France and to EMEA commercial operations. Earlier in her career, she practiced at law firms and focused on healthcare matters, including medical liability litigation and intellectual property. Valerie holds a master’s degree in Private law and a postgraduate diploma in Intellectual Property law from the University of Paris II Panthéon-Assas. She has been a member of the Paris Bar since 1999.

Executive Vice President, Head of Americas

Tibor Nemes

Tibor Nemes has a proven track record in the biotech and pharmaceutical industry in both Europe and in the United States. He has held leadership roles in engineering, process development, quality assurance and the manufacturing of biologics, solids, and sterile dosage forms.

Tibor joined Stallergenes Greer in 2016 as Global Head of Technical Operations before taking over as Head of the Americas in May 2018.

He previously spent eight years at Novartis where he held roles of increasing responsibility, most recently as the Global Operations Head, Tech Ops Manufacturing, Strategy and BDM&A where he headed Operations for Manufacturing Strategy and Business Development & Licensing within Global Technical Operations.

Prior to Novartis, Tibor Nemes held Engineering and Operations leadership roles at pharmaceutical and biotechnology companies including Novavax, Inc., Bristol-Myers Squibb Company, Elan Pharmaceuticals and Hypex, Inc.

General Manager France, Global Head of Pricing & Market Access

Dominique Pezziardi

Dominique Pezziardi was appointed General Manager France and Global Head of Pricing and Market Access in 2018. Dominique held roles of increasing responsibility in the pharmaceutical industry, holding positions in sales, marketing and strategy at local, regional and global levels. 

Prior to joining Stallergenes Greer in 2012, Dominique Pezziardi gained his expertise in several therapeutic fields including fertility, growth hormones, diabetes, orphan diseases, cardiology and medical devices, within pharmaceutical companies including Ciba, Sanofi and Merck Serono.

He successfully managed global product launches, life cycle development plans, mature franchises relaunches, alliances with strategic partners or more recently, corporate strategy development.

He graduated from a business school in Bordeaux, France and trained in pharmaco-economy in Milano, Italy.

Head of Commercial Europe and International

Petr Tor

Petr Tor joined Stallergenes Greer in 2010 with significant international experience in the pharmaceutical industry, holding positions in finance, marketing and sales at local and regional levels.

Petr Tor gained his expertise in several therapeutic fields including asthma, cardio, diabetes, glaucom, antibiotics, antifungals and HIV within Merck & Co. known as MSD in Europe, where he spent 16 years.

He joined Stallergenes Greer as General Manager of the Czech and Slovak subsidiary and since 2014 he held commercial responsibilities for various regions with growing scope and complexity in Europe, Middle East and Africa.

He is Czech, graduated from Chemistry at Institute of Chemical Technology in Prague and got diploma in Accounting and Finance at MBA Rochester Institute of Technology, New York US Business School in Prague.

Executive Vice President Operations Europe

Amer Jaber

Amer Jaber was appointed Executive Vice President Operations Europe in 2019. Amer has extensive international experience in the pharmaceutical industry and previously held positions in finance, marketing and sales at both local and regional levels.

Prior to joining Stallergenes Greer, Amer Jaber was Head of Biotechnology Operations at R-Pharm where he was in charge of developing the long-term strategy and execution of in-house and external technical operations for CMC Development and Manufacturing. He was previously Head of Global Biotech Development and Manufacturing for Technical Operations and Managing Director of UCB Switzerland. Before joining UCB, he held roles of increasing responsibility in product development, quality and manufacturing at Mondobiotech, Serono International and Rivopharm. 

He holds a PhD in Medicinal Organic Chemistry from the University of Geneva and has completed various executive leadership programs at Harvard Business School, IMD and Babson College.